# Trintellix (vortioxetine hydrobromide) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/vortioxetine

> The next catalyst for Trintellix (vortioxetine hydrobromide), sponsored by TAKEDA PHARMACEUTICAL CO LTD (TAK), is its topline data readout, Sep to Dec 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Trintellix (vortioxetine hydrobromide) |
| Codes |  |
| Sponsor | TAKEDA PHARMACEUTICAL CO LTD (TAK) https://sec-api.dev/companies/tak/catalysts |
| Indications | [Major Depressive Disorder](https://sec-api.dev/indications/major-depressive-disorder) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### November 13, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA204447 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20201113, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product TRINTELLIX (VORTIOXETINE HYDROBROMIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204447%22

### January 22, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA204447 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20210122, review_priority PRIORITY; sponsor_name TAKEDA PHARMS USA; product TRINTELLIX (VORTIOXETINE HYDROBROMIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204447%22

### August 23, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA204447 SUPPL-26 (Efficacy): submission_status AP, submission_status_date 20230823, review_priority PRIORITY; sponsor_name TAKEDA PHARMS USA; product TRINTELLIX (VORTIOXETINE HYDROBROMIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204447%22

### Sep to Dec 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Major Depressive Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07204314 (A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-30 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07204314

### September 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Major Depressive Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07204314 (A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-30 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07204314

## Same indication

- [ALTO-300](https://sec-api.dev/pdufa/alto-300) (ANRO)
- [Azetukalner](https://sec-api.dev/pdufa/azetukalner) (XENE)
- [BHV-7000](https://sec-api.dev/pdufa/bhv-7000) (BHVN)
- [Brenipatide](https://sec-api.dev/pdufa/brenipatide) (LLY)
- [Evifacotrep](https://sec-api.dev/pdufa/evifacotrep) (BMY)
- [GM-2505](https://sec-api.dev/pdufa/gm-2505) (ABBV)
- [Icalcaprant](https://sec-api.dev/pdufa/icalcaprant) (ABBV)
- [Caplyta (lumateperone tosylate)](https://sec-api.dev/pdufa/lumateperone) (JNJ)
- [Lysergide tartrate](https://sec-api.dev/pdufa/lysergide) (DFTX)
- [Navacaprant](https://sec-api.dev/pdufa/navacaprant) (NMRA)
- [NBI-1065845](https://sec-api.dev/pdufa/nbi-1065845) (NBIX)
- [NBI-1070770](https://sec-api.dev/pdufa/nbi-1070770) (NBIX)
- [Psilocybin](https://sec-api.dev/pdufa/psilocybin) (CMPS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/vortioxetine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Trintellix (vortioxetine hydrobromide) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/vortioxetine

```bibtex
@misc{secapidev_pdufa_vortioxetine_20261116,
  title        = {Trintellix (vortioxetine hydrobromide) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/vortioxetine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_vortioxetine_20261116","title":"Trintellix (vortioxetine hydrobromide) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/vortioxetine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
